ArticleBMC biology2026
CMMSCL-DPI: cross-modal multi-structural contrastive learning for predicting drug-protein interactions.
Article in BMC biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPredicting drug-protein interactions (DPI) is essential for effective and safe drug discovery. Although deep learning methods have been extensively applied to DPI prediction, effectively leveraging the multi-structural and multimodal data on drugs and proteins to enhance prediction accuracy remains a significant challenge.
resultsThis study proposes CMMSCL-DPI, a cross-modal multi-structural contrastive learning model. CMMSCL-DPI applies contrastive learning to the multi-dimensional structural features of proteins and drugs separately and integrates interaction features from a DPI heterogeneous graph network to facilitate cross-modal contrastive learning. This approach effectively captures the key differences and similarities between proteins and drugs, significantly enhancing the model's generalization capabilities for novel drug-target pairs. Experimental results across four benchmark datasets demonstrate that CMMSCL-DPI outperforms five state-of-the-art baseline models in overall performance. Additionally, the model successfully identified an unreported drug-protein interaction, which was subsequently validated through all-atom molecular dynamics simulations.
conclusionsThis case study not only confirms the predictive accuracy of CMMSCL-DPI but also underscores its potential in discovering novel protein-ligand interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.